Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4894026 | 0.99 | HTR4 (0.73) | HTR4DRD2 | |
| SCHEMBL10413092 | 0.91 | HTR4 (0.79) | HTR4DRD2 | |
| SCHEMBL4895495 | 0.87 | HTR4 (0.70) | HTR4DRD2 | |
| SCHEMBL4892917 | 0.87 | HTR4 (0.70) | HTR4DRD2 | |
| SCHEMBL6237104 | 0.87 | HTR4 (0.70) | HTR4DRD2 | |
| SCHEMBL10412169 | 0.87 | HTR4 (0.76) | HTR4DRD2 | |
| SCHEMBL10523919 | 0.87 | HTR4 (0.76) | HTR4DRD2 | |
| Hydrochloric Acid SCHEMBL4895999 | 0.87 | HTR4 (0.69) | HTR4DRD2 | |
| Hydrochloric Acid SCHEMBL6233948 | 0.87 | HTR4 (0.69) | HTR4DRD2 | |
| Hydrochloric Acid SCHEMBL4894767 | 0.87 | HTR4 (0.69) | HTR4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070944-A1 | Novel methods using aminobenzoic acid compounds | EISAI CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070015789-A1 | Novel methods using aminobenzoic acid compounds | EISAI CO., LTD. (JP) | 2007-01-18 | — | — | US | disclosed |
| WO-2005007600-A2 | NOVEL METHODS USING AMINOBENZOIC ACID COMPOUNDS | EISAI CO., LTD. (JP) | 2005-01-27 | — | — | WO | disclosed |
| US-5631402-A | ETHERIFYING 4-AMINO-5-HALOGEN-SALICYLIC ACID WITH ALKYNOL IN PRESENCE OF TRIPHENYLPHOSPHINE AND DIALKYLAZOCARBOXYLATE | EISAI CO., LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5599972-A | GASTROINTESTINAL DISORDERS | EISAI CO., LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5578603-A | TREATMENT FOR ALZHEIMER*S DISEASE, GAASTROINTRESTINAL DISORDERS | EISAI CO., LTD. (JP) | 1996-11-26 | — | — | US | disclosed |
| US-5389643-A | Antiseerotonine, anticholinergic agents | EISAI CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0554794-A1 | Aminobenzoic acid derivatives | Eisai Co., Ltd. (JP) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015789-A1 | Novel methods using aminobenzoic acid compounds | GRIN2B, HTR5A, AADAT | HTR4 133/4885DRD2 2122/4885 |
| US-20080070944-A1 | Novel methods using aminobenzoic acid compounds | GRIN2B, HTR5A, AADAT | HTR4 133/4885DRD2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.